ABIVAX Société Anonyme (ABVX) Projected to Post Earnings on Monday

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($1.59) per share and revenue of $3.11 million for the quarter.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX traded up $0.02 on Tuesday, hitting $5.69. 308,552 shares of the company were exchanged, compared to its average volume of 140,209. ABIVAX Société Anonyme has a twelve month low of $4.77 and a twelve month high of $14.71. The company's 50 day moving average price is $6.32 and its 200-day moving average price is $7.02.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ABVX. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Woodline Partners LP raised its position in shares of ABIVAX Société Anonyme by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock worth $1,262,000 after purchasing an additional 153,788 shares during the period. Millennium Management LLC raised its position in shares of ABIVAX Société Anonyme by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after purchasing an additional 56,235 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of ABIVAX Société Anonyme by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after purchasing an additional 2,595 shares during the period. Finally, Bank of America Corp DE raised its holdings in ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.